Drug Profile
Research programme: CNS therapeutics - Denali/Blaze Bioscience/Fred Hutchinson Cancer Research Center
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Blaze Bioscience; Fred Hutchinson Cancer Research Center
- Developer Blaze Bioscience; Denali Therapeutics Inc; Fred Hutchinson Cancer Research Center
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in CNS-disorders in USA
- 25 Aug 2016 Denali Therapeutics, Fred Hutchinson Cancer Research Center and Blaze Bioscience agree to co-develop CNS therapeutics
- 25 Aug 2016 Early research in CNS disorders in USA (unspecified route)